AI platform for CT coronary angiography applications
AI Driven National Platform for CT cOronary Angiography for clinicaL and industriaL applicatiOns Registry (APOLLO)
This study is testing a new AI platform that helps doctors quickly and accurately analyze heart scans for patients with coronary artery disease to improve their treatment and care.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 8000 (estimated) |
| Ages | 21 Years to 80 Years |
| Sex | All |
| Sponsor | National Heart Centre Singapore Academic / other |
| Drugs / interventions | radiation |
| Locations | 3 sites (Singapore and 2 other locations) |
| Trial ID | NCT05509010 on ClinicalTrials.gov |
What this trial studies
This study aims to develop an AI-driven national platform for CT coronary angiography that automates the processes of anonymization, reporting, Agatston scoring, and plaque quantification in patients with coronary artery disease (CAD). By leveraging artificial intelligence, the platform seeks to enhance diagnostic accuracy and efficiency, reducing the time required for report generation and minimizing inter-observer variability. The initiative addresses the growing prevalence of CAD and aims to improve clinical management and prognosis through better prediction of pharmacotherapy responses.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals aged 21 and older who are clinically indicated for evaluation by CT coronary angiography.
Not a fit: Patients with known complex congenital heart disease or those requiring immediate invasive angiography for reasons other than CAD may not benefit from this study.
Why it matters
Potential benefit: If successful, this platform could significantly streamline the diagnostic process for CAD, leading to improved patient outcomes and more effective treatment strategies.
How similar studies have performed: Other studies have shown success with AI applications in medical imaging, indicating a promising potential for this approach in improving CAD diagnostics.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age ≥21 years old 2. Signed informed consent 3. Clinically indicated for evaluation by CTCA Exclusion Criteria: 1. Individuals unable to provide informed consent 2. Known complex congenital heart disease 3. Planned invasive angiography for reasons other than CAD 4. Non-cardiac illness with life expectancy \< 2 years 5. Pregnancy 6. Concomitant participation in another clinical trial in which subject is subject to investigational drug or device 7. Cardiac event and/or coronary revascularization (percutaneous coronary intervention (PCI) and/or coronary artery bypass grafting (CABG) and/or valvular repair/replacement prior to CTCA 8. Glomerular Filtration Rate ≤ 30mL/min 9. Known allergy to iodinated contrast agent 10. Contraindications to beta blockers or nitroglycerin or adenosine
Where this trial is running
Singapore and 2 other locations
- National Heart Centre Singapore — Singapore, Singapore (Recruiting)
- National University Hospital — Singapore, Singapore (Recruiting)
- Tan Tock Seng Hospital — Singapore, Singapore (Recruiting)
Study contacts
- Principal investigator: Liang Zhong — National Heart Centre Singapore
- Study coordinator: Associate Professor Zhong Liang
- Email: zhong.liang@nhcs.com.sg
- Phone: +65 6704 2237
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.